Fidelity Investments’s Soleno Therapeutics SLNO Stock Holding History

Fidelity Investments’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,788,410	Closed	-$194M	–	5702
2026 Q1	$194M	Sell	5,788,410 -2,290,894	-28%	-$89.8M	0.01%	867
2025 Q4	$374M	Buy	8,079,304 +79,622	+1%	+$4.37M	0.02%	613
2025 Q3	$541M	Buy	7,999,682 +4,661,824	+140%	+$346M	0.03%	465
2025 Q2	$280M	Buy	3,337,858 +1,104,385	+49%	+$82.7M	0.02%	691
2025 Q1	$160M	Buy	2,233,473 +1,420,446	+175%	+$69.2M	0.01%	901
2024 Q4	$36.5M	Buy	813,027 +147,653	+22%	+$7.65M	﹤0.01%	1510
2024 Q3	$33.6M	Buy	665,374 +665,363	+6,048,755%	+$31.9M	﹤0.01%	1533
2024 Q2	$449	Buy	+11	New	+$466	﹤0.01%	4873

Fidelity Investments's SLNO Position: Q2 2026 in Review

Fidelity Investments sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 5,788,410 shares — an estimated $194M sold.

Fidelity Investments first reported a position in SLNO in Q2 2024 and held it in 8 quarters. The position peaked at $541M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Fidelity Investments reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Fidelity Investments sold 5,788,410 Soleno Therapeutics shares in Q2 2026, an estimated $194M.
Fidelity Investments first reported a position in Soleno Therapeutics in Q2 2024 and held it in 8 quarters.
Fidelity Investments's Soleno Therapeutics position peaked at $541M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.